CD274 and lung carcinoma: Therefore, we investigated the impact of EGFR inhibition on the expression of antigen presenting molecules and PD-L1 proteins in lung cancer cell lines with a wide range of in vitro sensitivity to erlotinib, one of the three EGFR inhibitors that have been approved for the first line therapy of EGFR-mutated lung cancer.